No items found.
Today, there is a need for more accurate and personalized RNA-based cancer diagnostics. RNA visualization and sequencing are an integrated part of R&D programs in the pharmaceutical industry, and are increasingly used at cancer centers, institutes and hospitals to provide more accurate diagnosis and subsequent personalized treatment regimens for patients.
Our biotech company, MultiplexDX, aims to drastically increase the number of cancer survivors through personalized diagnostics that lead to tailored, effective, and life-saving treatment. We want to bring to market a reliable, accurate, quantitate, cost-effective, and multiplexed diagnostic test for cancer, which can accurately identify and quantify cancer biomarkers in human tissues.
We are looking for an experienced Senior Molecular Biologist ─ Fluorescent In Situ Hybridization (FISH) to take the lead in planning, conducting, and optimizing RNA-based FISH experiments.
In this multifaceted role, you will help advance our next pipeline of designed diagnostic products, solve technical obstacles, test different concepts in the laboratory, read scientific papers, track R&D costs, study patents, and generate new ideas in collaboration with our team of innovative Molecular Biologists.
You will report to the Director of Research & Development and Chief Operating Officer and be based at the headquarters in Bratislava, Slovakia.
MultiplexDX recently received an EIC Accelerator grant, which guarantees two years of funding for this position with the possibility of an extension.
We offer a great career with development opportunities in a highly motivating and professional environment. You may be looking for a new career path or simply looking to contribute to a small, hard-working organization with the ambition to make a difference.
You will be offered the opportunity to spearhead the next ground-breaking diagnostic technologies involving RNA-based FISH.
The job will be challenging and rewarding at the same time. You will have world class colleagues, flexible working hours, 5 weeks of paid holiday, and a negotiable salary commensurate to your qualifications (starting from €2000/month). This position will be funded for at least two years with the possibility of an extension under a recently awarded EIC Accelerator grant.
Application deadline is February 29th, 2020. Please send the application including your CV or resume with the names of 3 references and a cover letter to firstname.lastname@example.org.
Your application will be treated in accordance with our policies for processing of personal data and the General Data Protection Regulation of the EU.
MultiplexDX’s diagnostic products combine specific, precise, automated, high-throughput, multiplexed and quantitative RNA visualization and sequencing to come up with a specific “barcode” for each cancer, which suggests a unique, personalized treatment strategy. In MultiplexDX’s diagnostic tests, multiplexing stands for cross-validating test results by using two independent perspectives, visualization and sequencing. This multiplexed platform provides the most accurate clinical parameters of a patient’s cancer profile, which enables an oncologist to make an evidence-based decision and target treatment quickly, directly, and more accurately.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.